ID: h-8e4e15dc
Hypothesis
Branched-Chain Amino Acid Transamination Inhibition to Modulate Neurotransmitter Homeostasis
Branched-Chain Amino Acid Transamination Inhibition to Modulate Neurotransmitter Homeostasis.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 4 oppose
🧪 Overview
Branched-Chain Amino Acid Transamination Inhibition to Modulate Neurotransmitter Homeostasis
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["BCAT1/BCAT2<br/>Hypothesis Target"]
B["Pathway Dysregulation<br/>Cited Mechanism"]
C["Cellular Response<br/>Stress or Clearance Change"]
D["Neural Circuit Effect<br/>Synapse/Glia Vulnerability"]
E["Neurodegeneration<br/>Disease-Relevant Outcome"]
A --> B
B --> C
C --> D
D --> E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style B fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix4 supports4 contradicts
Supports
Metabolomic studies report elevated plasma BCAAs in AD patients, with decreased utilization in brain tissue
Supports
BCAT1 expression is reduced in AD hippocampus, correlating with decreased glutamate recycling capacity
Supports
BCAA supplementation paradoxically improves cognitive function in some aging studies
Supports
Mouse model studies demonstrate that BCAT inhibition reduces glutamate-mediated excitotoxicity in stroke models
Contradicts
BCAA supplementation shows mixed cognitive effects in meta-analyses - larger trials fail to replicate cognitive benefits
Contradicts
BCAT has dual functions - global inhibition could disrupt glutamate homeostasis unpredictably, causing excitotoxicity or synaptic failure
Contradicts
Brain BCAT activity is highly regulated by leucine which affects mTOR signaling - distinguishing BCAT-specific effects challenging
Contradicts
Industry programs (Janssen) for BCAT inhibitors dropped due to unclear efficacy
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — BCAT1
No curated PDB or AlphaFold mapping for BCAT1 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for BCAT1/BCAT2 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for BCAT1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.9%
Volatility
Low
0.0069
Events (7d)
3
Price History
▲17.6%💾 Resource Usage
LLM Tokens
38,010
$0.1140
Total Cost
$0.1140
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF CRISPR-Cas9 editing is used to knock down BCAT2 in SH-SY5Y neuroblastoma cells (≥70% knockdown efficiency), THEN intracellular tyrosine and tryptophan will accumulate ≥2-fold while dopamine and ser | Accumulation of aromatic amino acid precursors (tyrosine, tryptophan) and corresponding decrease in downstream monoamine neurotransmitters | — no observation — | pending | 0.35 |
| IF primary mouse cortical neurons are treated with the BCAT inhibitor gabapentin (100 µM, 48h) or vehicle control, THEN glutamate and GABA levels will decrease by ≥25% compared to vehicle controls as | Significant reduction in extracellular glutamate and GABA concentrations (≥25% decrease) following BCAT inhibition in neuronal cultures | — no observation — | pending | 0.45 |
🔮 Falsifiable Predictions (2)
pendingconf 45%
IF primary mouse cortical neurons are treated with the BCAT inhibitor gabapentin (100 µM, 48h) or vehicle control, THEN glutamate and GABA levels will decrease by ≥25% compared to vehicle controls as measured by LC-MS/MS.
Predicted outcome: Significant reduction in extracellular glutamate and GABA concentrations (≥25% decrease) following BCAT inhibition in neuronal cultures
Falsification: Glutamate and GABA levels remain unchanged or increase following BCAT inhibitor treatment (change <20% from baseline)
pendingconf 35%
IF CRISPR-Cas9 editing is used to knock down BCAT2 in SH-SY5Y neuroblastoma cells (≥70% knockdown efficiency), THEN intracellular tyrosine and tryptophan will accumulate ≥2-fold while dopamine and serotonin decrease ≥30% within 72 hours post-transfection.
Predicted outcome: Accumulation of aromatic amino acid precursors (tyrosine, tryptophan) and corresponding decrease in downstream monoamine neurotransmitters
Falsification: Amino acid and neurotransmitter levels remain within 20% of wild-type levels despite confirmed BCAT2 knockdown, indicating BCAT2 is not rate-limiting for neurotransmitter precursor metabolism
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.